Events and Presentations

Nabriva Therapeutics Provides Business and Development Update and Reports 2016 Financial Results

Events and Presentations | Investor News | Shareholder Information
Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006
Press Releases
DateTitle  
03/24/17Nabriva Therapeutics Provides Business and Development Update and Reports 2016 Financial Results
VIENNA, Austria and KING OF PRUSSIA, Pa., March 24, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics AG (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today provided a business and clinical development update and reported its financial results for the year ended December 31, 2016. “For the last 12 months, we have been executing o... 
 Printer Friendly Version
02/27/17Nabriva Therapeutics to Present at the Cowen and Company 37th Annual Healthcare Conference
VIENNA, Austria and KING OF PRUSSIA, Pa., Feb. 27, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics AG (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today announced that Colin Broom, M.D., chief executive officer of Nabriva Therapeutics, will provide a company overview and business update at the Cowen and Company 37th Annual Health... 
 Printer Friendly Version
02/08/17Nabriva Therapeutics to Participate in Two Investor Conferences in February
VIENNA, Austria, and KING OF PRUSSIA, Pa., Feb. 08, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics AG (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today announced that Colin Broom, M.D., Chief Executive Officer of Nabriva Therapeutics, will provide a company overview and business update at the following conferences in February. ... 
 Printer Friendly Version
02/02/17Nabriva Therapeutics Confirms No Sample Size Adjustment Required for LEAP 1 Phase 3 Trial of Lefamulin in Community Acquired Bacterial Pneumonia
LEAP 1 top-line efficacy and safety data expected in 3Q17 VIENNA, Austria, and KING OF PRUSSIA, Pa., Feb. 02, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics AG (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today announced that following a blinded interim analysis, an independent committee recommended no sample size adjustment fo... 
 Printer Friendly Version